Company Profile

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE1445.8020.75 (+1.46 % )
PREV CLOSE (Rs.) 1425.05
OPEN PRICE (Rs.) 1432.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3098
TODAY'S LOW / HIGH (Rs.)1415.50 1476.30
52 WK LOW / HIGH (Rs.)1258 1805
NSE1446.05 20.65 (+1.45 % )
PREV CLOSE(Rs.) 1425.40
OPEN PRICE (Rs.) 1438.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1446.05 (47 )
VOLUME 112071
TODAY'S LOW / HIGH(Rs.) 1421.00 1478.95
52 WK LOW / HIGH (Rs.)1206 1807.5

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 2.77
TTM EPS (Rs.) 28.50
P/E Ratio 50.74
Book Value (Rs.) 79.50
Face Value (Rs.) 10
MCap (Rs. in Mn) 244927.24
Price/Earning (TTM) 43.21
Price/Sales (TTM) 7.75
Price/Book (MRQ) 18.19
PAT Margin (%) 3.41
ROCE (%) 16.51
Incorporation Year : 1924

Management Info :

R S Karnad - Chairman S Venkatesh - Managing Director

Registered Office :

Address : Dr Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone : 022-24959595

Email : askus@gsk.com

Website : www.gsk-india.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
05Apr04-05-2021$GlaxosmithKline Pharmaceuticals informs about certificate GlaxosmithKline Pharmaceutic

In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, GlaxosmithKline Pharmaceuticals has informed that it has enclosed a copy of the Certificate received from Kfintech, the Registrar and share Transfer Agent of the Company, for the quarter ended 31st March 2021.

The above information is a part of company’s filings submitted to BSE.

In Compliance with Regulation 74(5) of SEBI (Depositories and P..
04Mar03-04-2021$GlaxoSmithKline Pharmaceuticals informs about newspaper advertisement GlaxoSmithKline Pharmaceutic

Pursuant to Clause 47 of the Listing and Disclosure Requirements Regulations, 2015 LODR) GlaxoSmithKline Pharmaceuticals has informed that it has enclosed the advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of IEPF Notice.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Clause 47 of the Listing and Disclosure Requirement..
07Jan01-07-2021$Glaxosmithkline Pharmaceuticals informs about board meeting Glaxosmithkline Pharmaceutic
Glaxosmithkline Pharmaceuticals has informed that the Board of Directors at its meeting held on 7th January 2021 have approved the following changes in Board of Directors of the Company. Raju Krishnaswamy has resigned has a Director of the Company with effect from 27th January 2021. The Board of Directors of the Company at its meeting held today, has appointed Mark Dawson as a Non - Executive Director of the Company effective 28th January, 2021.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Pharmaceuticals has informed that the Board of..
07Jan01-07-2021$ Board Meeting Intimation for Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2020. Board Meeting Intimation fo
GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2021 ,inter alia, to consider and approve Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations,2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be held on Friday, 5th February 2021, inter-alia, to consider approval of Un-audited financial results for the quarter and nine months ended 31 st December 2020.
GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the m..
28Dec12-28-2020$Glaxosmithkline Pharmaceuticals informs about closure of trading window Glaxosmithkline Pharmaceutic

Glaxosmithkline Pharmaceuticals has informed that the in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Company’s shares is closed from Friday, 1st January, 2021 and shall reopen on Wednesday, 10th February, 2021 i.e. after the approval and declaration of Un-audited Financial Results for the quarter and nine months ended 31st December, 2020 by the Board of Directors at its meeting scheduled to be held on 5th February 2021.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Pharmaceuticals has informed that the in terms..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit1573.51100.5
Gross Profit 2125.4 3225
Operating Profit 2206.67360.1
Net Sales 8584.232246.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 15245.80 (1.32%)
M.Cap ( in Cr)
32396.26
Pfizer (BSE)
 4797.80 (3.88%)
M.Cap ( in Cr)
21948.85
Alkem Laboratories (BSE)
 2832.25 (4.66%)
M.Cap ( in Cr)
33863.80
Sanofi India (BSE)
 8227.25 (1.04%)
M.Cap ( in Cr)
18947.87
Procter&Gamble Healt (BSE)
 6362.40 (1.17%)
M.Cap ( in Cr)
10561.19
Shareholding Pattern More
PROMOTERS 75 %
MUTUAL FUNDS/UTI 3.87 %
NON-INSTITUTION 12.56 %
FI/BANKS/INSURANCE 1.44 %
FII 0 %
GOVERNMENT 0 %
MF HOLDINGS More
F & O Quotes